Lipid nanoparticles for engineering next generation CAR T cell immunotherapy
Nanoscale Horizons · 2026
DOI: 10.1039/d5nh00432b ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nanoscale Horizons, 2026. Verfasst von Melgious Jin Yan Ang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania, USA. mjmitch@seas.upenn.edu. Hauptthemen laut MEDLINE: Nanoparticles, Liposomes, Immunotherapy, Adoptive, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Antigen-presenting cell–mimetic lipid nanoparticles (aLNPs) offer a powerful strategy to streamline CAR T cell immunotherapy by enabling one-step T cell activation and CAR transgene delivery ex vivo .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania, USA. mjmitch@seas.upenn.edu.
- Bioprocessing Technology Institute (BTI), Agency for Science, Technology and Research (A*STAR), Republic of Singapore, Singapore.
Zitieren
APA
Ang, M. J. Y., Metzloff, A. E., Thatte, A. S., & Mitchell, M. J. (2026). Lipid nanoparticles for engineering next generation CAR T cell immunotherapy. Nanoscale Horizons. https://doi.org/10.1039/d5nh00432b
Vancouver
Ang MJY, Metzloff AE, Thatte AS, Mitchell MJ. Lipid nanoparticles for engineering next generation CAR T cell immunotherapy. Nanoscale Horizons. 2026. doi:10.1039/d5nh00432b
BibTeX
@article{Ang2026,
author = {Ang, Melgious Jin Yan and Metzloff, Ann E and Thatte, Ajay S and Mitchell, Michael J},
title = {Lipid nanoparticles for engineering next generation CAR T cell immunotherapy},
journal = {Nanoscale Horizons},
year = {2026},
doi = {10.1039/d5nh00432b}
}
EUVIMED